Alpha psychiatryPub Date : 2026-10-26eCollection Date: 2026-10-01DOI: 10.31083/AP53584
Lin Zhang, Jie Zhang, Lu Wen, Xinming Pan, Hongjun Mao, Xiao-E Lang, Junjun Liu, Xiangyang Zhang
{"title":"Depression's Shadow in First-Onset Schizophrenia: Mapping the Burden and Clinical Significance in Drug-Naïve Patients.","authors":"Lin Zhang, Jie Zhang, Lu Wen, Xinming Pan, Hongjun Mao, Xiao-E Lang, Junjun Liu, Xiangyang Zhang","doi":"10.31083/AP53584","DOIUrl":"10.31083/AP53584","url":null,"abstract":"<p><strong>Background: </strong>Severe depressive symptoms (SDS) are common in patients with schizophrenia (SZ) and are associated with poor prognosis, reduced quality of life, and an increased risk of suicide. However, the prevalence of SDS and its key associated factors in first-onset drug-naïve patients with SZ remain unclear.</p><p><strong>Methods: </strong>This cross-sectional study enrolled 320 inpatients diagnosed with SZ according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), including 164 males and 156 females, aged 18 to 60 years, with a mean disease duration of 2.18 years. The severity of psychotic symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS), anxiety symptoms were evaluated using the Hamilton Anxiety Rating Scale (HAMA), and SDS were assessed using the Hamilton Depression Rating Scale (HAMD). A history of suicide attempts was obtained through standardized interviews. The Kolmogorov-Smirnov test was used to assess the normality of continuous variables. Bonferroni correction was applied to all between-group comparisons of continuous and categorical variables. Univariate analyses and multivariable logistic regression were performed to identify factors independently associated with SDS. A sensitivity analysis excluding patients with a disease duration greater than 12 months was conducted to assess the robustness of the findings.</p><p><strong>Results: </strong>Among the 320 patients with SZ, 159 (49.7%) met the criteria for comorbid SDS. After adjustment for age, sex, disease duration, and marital status, multivariable logistic regression analysis demonstrated that higher PANSS scores (OR = 1.045, 95% CI: 1.024 to 1.067, <i>p</i> < 0.001), higher HAMA scores (OR = 1.284, 95% CI: 1.198 to 1.376, <i>p</i> < 0.001), and a history of suicide attempts (OR = 1.513, 95% CI: 1.222 to 1.875, <i>p</i> < 0.001) were independently associated with comorbid SDS. Excluding patients with a disease duration greater than 12 months (n = 138) did not materially alter the results. Furthermore, a combined model incorporating these three variables demonstrated excellent discriminatory performance, with an area under the receiver operating characteristic curve (AUC) of 0.937 (95% CI: 0.904 to 0.958, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Severe depressive symptoms are highly prevalent among first-onset, drug-naïve patients with schizophrenia and are independently associated with more severe psychotic symptoms, greater anxiety severity, and a history of suicide attempts. These findings provide important evidence to support early screening and targeted interventions for this vulnerable patient population.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"53584"},"PeriodicalIF":2.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-23eCollection Date: 2026-10-01DOI: 10.31083/AP53996
Álvaro Moleón-Ruiz, Lucía Duque-Fernández, Clara Regidor, Paloma Álvarez de Toledo, Gonzalo Martín-García, Lorena García-Fernández, Francisco Javier Narbona-Antunez, Luis Gutiérrez-Rojas, Roberto Rodriguez-Jimenez, Manuela Martín-Bejarano
{"title":"Accelerated Multi-Target Theta-Burst Stimulation for Obsessive-Depressive-Anxious Symptoms: Real-World Outcomes of the aTTODA Protocol.","authors":"Álvaro Moleón-Ruiz, Lucía Duque-Fernández, Clara Regidor, Paloma Álvarez de Toledo, Gonzalo Martín-García, Lorena García-Fernández, Francisco Javier Narbona-Antunez, Luis Gutiérrez-Rojas, Roberto Rodriguez-Jimenez, Manuela Martín-Bejarano","doi":"10.31083/AP53996","DOIUrl":"10.31083/AP53996","url":null,"abstract":"<p><strong>Background: </strong>Obsessive-compulsive symptoms frequently co-occur with depression and anxiety, contributing to a complex and potentially treatment-resistant clinical phenotype. Although transcranial magnetic stimulation (TMS) is an established treatment option for obsessive-compulsive disorder (OCD), many patients continue to experience residual symptoms across multiple domains. Multi-target neuromodulation approaches may help address overlapping neural circuits. This study evaluated the real-world effectiveness and feasibility of an accelerated Triple-Target Obsessive-Depressive-Anxious (aTTODA) theta-burst stimulation protocol.</p><p><strong>Methods: </strong>In this naturalistic cohort study, 25 patients with treatment-resistant depressive-anxious disorder and comorbid OCD were treated with TMS at a specialized neuropsychiatric center. All patients received the accelerated aTTODA protocol, consisting of 30 sessions delivered over 3 weeks. Obsessive-compulsive, depressive, and anxiety symptoms were assessed at baseline and post-treatment using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), 17-item Hamilton Depression Rating Scale (HDRS-17), and Hamilton Anxiety Rating Scale (HAM-A), respectively.</p><p><strong>Results: </strong>Treatment with the aTTODA protocol was associated with significant improvements across all symptom domains (all <i>p</i> < 0.001), with large within-group effect sizes (Cohen's d ≥1.0). Mean symptom reductions were 32.7% for the Y-BOCS, 44.6% for the HDRS-17, and 42.1% for the HAM-A. For OCD symptoms, 40% of patients met response criteria and 20% achieved remission. A shift toward lower Y-BOCS severity categories was also observed following treatment, suggesting broad clinical improvement beyond changes in mean symptom scores.</p><p><strong>Conclusions: </strong>In this complex, treatment-resistant population, the accelerated multi-target aTTODA protocol was associated with clinically meaningful improvements across obsessive-compulsive, depressive, and anxiety symptom domains. These preliminary findings support the feasibility of time-efficient, circuit-based neuromodulation strategies. However, controlled randomized, blinded, sham-controlled trials are needed to establish efficacy, durability of treatment effects, and optimal patient selection.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"53996"},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-23eCollection Date: 2026-10-01DOI: 10.31083/AP51419
Julia Karska, Błażej Misiak
{"title":"Inflammation and Immunophenotypes in Schizophrenia Spectrum Disorders: Current Knowledge and Advances.","authors":"Julia Karska, Błażej Misiak","doi":"10.31083/AP51419","DOIUrl":"10.31083/AP51419","url":null,"abstract":"","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"51419"},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-23eCollection Date: 2026-10-01DOI: 10.31083/AP53136
Liudmila Smirnova, Alexander Seregin, Evgeny Ermakov, Maria Zavialova, Elena Dmitrieva, Svetlana Novikova, German Simutkin, Elena Kornetova, Svetlana Ivanova
{"title":"Minor Proteins Involved in Neuronal Functions in Serum of Patients With Major Mental Disorders According to Proteomic Analysis.","authors":"Liudmila Smirnova, Alexander Seregin, Evgeny Ermakov, Maria Zavialova, Elena Dmitrieva, Svetlana Novikova, German Simutkin, Elena Kornetova, Svetlana Ivanova","doi":"10.31083/AP53136","DOIUrl":"10.31083/AP53136","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia (SCZ) and bipolar disorder (BD) share common clinical features, complicating the identification of specific peripheral biomarkers. The objective of this study was to identify biomarkers that specifically characterize different clinical forms of BD and SCZ.</p><p><strong>Methods: </strong>A comparative proteomic analysis of serum samples from patients with SCZ and BD, as well as healthy controls, was performed using untargeted mass spectrometry to identify differentially expressed proteins. In an expanded cohort, accounting for clinical heterogeneity, the levels of six minor proteins (N-methyl-D-aspartate receptor 1 (NMDAR1), ankyrin 3 (ANK3), ankyrin repeat domain-containing protein 12 (ANKRD12), low-density lipoprotein receptor-related protein 2 (LRP2), dermcidin (DCD), and anti-NMDAR antibodies) were quantified using enzyme-linked immunosorbent assay (ELISA) and targeted mass spectrometry (for NMDAR1).</p><p><strong>Results: </strong>Comparative serum proteomic analysis identified 440 unique proteins in healthy controls versus 221 in patients with SCZ, and 474 unique proteins in healthy controls versus 55 in patients with BD. Quantitative analysis revealed the following findings: (1) a significant increase in NMDAR1 protein levels in patients with BD experiencing a current depressive episode (BD-cDE); (2) decreased ANK3 levels in patients with BD-cDE and SCZ; (3) increased ANKRD12 protein levels in patients with SCZ characterized by predominant negative symptoms and in patients with BD-cDE; (4) decreased DCD levels in patients with SCZ in remission compared with those in the acute phase of the disease; and (5) significantly increased LRP2 levels in both BD and SCZ. Elevated anti-NMDAR antibody levels were more frequently observed in patients with BD, although absolute antibody levels were also increased in patients with acute-phase SCZ.</p><p><strong>Conclusions: </strong>These findings suggest a common mechanism of synaptopathy involving destabilization of the ANK3-NMDAR scaffold, accompanied by a compensatory neuroprotective response in both BD and SCZ. The identified alterations in the serum protein profile may serve as potential biomarkers for the differential diagnosis of these disorders as part of multimarker diagnostic panels.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"53136"},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Microbiota Dysbiosis and the Gut-Brain Axis in Psychiatric Disorders: Molecular Mechanisms, Clinical Evidence, and Therapeutic Perspectives.","authors":"Giuseppe Marano, Luca Conci, Leila Farsakh, Gianandrea Traversi, Osvaldo Mazza, Valentina Ricozzi, Silvia Rotondaro, Antonella Migliore, Esmeralda Capristo, Gianluca Franceschini, Eleonora Gaetani, Marianna Mazza","doi":"10.31083/AP54121","DOIUrl":"10.31083/AP54121","url":null,"abstract":"<p><p>The gut-brain axis provides a biologically plausible framework for understanding the bidirectional interactions among the intestinal microbiota, immune-inflammatory signaling, neuroendocrine regulation, neurotransmitter metabolism, and psychiatric symptoms. Although numerous recent reviews have examined individual psychiatric disorders, microbial composition, or microbiota-targeted therapies, the field still lacks a sufficiently integrated appraisal that clearly distinguishes associative findings from human studies, mechanistic evidence from preclinical research, and preliminary clinical interventions. This structured narrative review synthesizes clinical, translational, and preclinical studies across major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, and trauma-related conditions. The main literature search covered publications from January 2015 to January 2026; earlier foundational mechanistic studies of key relevance to gut-brain communication were also considered. Recurrent pathways include altered short-chain fatty acid production, tryptophan-kynurenine metabolism, immune-inflammatory activation, hypothalamic-pituitary-adrenal axis dysregulation, neurotransmitter-related signaling, impaired intestinal and blood-brain barrier integrity, and vagus nerve-mediated communication. Human studies predominantly demonstrate associations between microbial signatures and psychiatric phenotypes, symptom severity, inflammatory status, or treatment response, whereas preclinical models provide stronger mechanistic evidence that microbiota manipulation can influence behavioral, neurochemical, immune, and neuroendocrine outcomes. Probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation show therapeutic potential; however, the current evidence is limited by small sample sizes, methodological heterogeneity, insufficient standardization, and a lack of long-term validation. The distinctive contribution of this review is its structured comparison of three levels of evidence-human observational findings, experimental mechanistic studies, and emerging clinical interventions-thereby clarifying what has been consistently replicated, what remains mechanistically plausible, and what is not yet ready for routine application in psychiatric practice.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"54121"},"PeriodicalIF":2.9,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Right Superior Orbitofrontal Gray Matter Volume Reduction Mediates Executive Dysfunction in Schizophrenia Patients With Comorbid Metabolic Syndrome.","authors":"Hangyu Li, Xinyan Wu, Xinyue Chen, Ying Li, Shiji Peng, Rui Yu, Nian Liu","doi":"10.31083/AP52539","DOIUrl":"10.31083/AP52539","url":null,"abstract":"<p><strong>Background: </strong>Patients with schizophrenia (SCZ) are at a markedly increased risk of developing metabolic syndrome (MetS), which substantially reduces life expectancy and adversely affects treatment adherence. Although cognitive impairment is a core feature of SCZ, the neurobiological mechanisms linking comorbid MetS to cognitive dysfunction remain complex and incompletely understood. Previous studies have primarily focused on the effects of abnormal brain function and white matter abnormalities on cognition, whereas the contribution of gray matter volume (GMV) alterations in the context of comorbid MetS has received comparatively less attention. Accordingly, this study examined GMV alterations in patients with SCZ and comorbid MetS and evaluated whether these alterations mediate the association between MetS and cognitive impairment.</p><p><strong>Methods: </strong>Sixty clinically stable patients with SCZ receiving risperidone or clozapine were recruited, including 28 meeting the diagnostic criteria for MetS (SCZ-MetS) and 32 without MetS (SCZ-nMetS), together with 31 demographically matched healthy controls (HCs). High-resolution structural magnetic resonance imaging (MRI) scans were analyzed using voxel-based morphometry (VBM) to quantify GMV. Mediation analyses were performed to determine whether GMV alterations mediated the association between MetS and cognitive function.</p><p><strong>Results: </strong>Compared with the HC group, both the SCZ-nMetS and SCZ-MetS groups exhibited widespread GMV reductions involving the cingulate cortex, left temporal lobe, frontal regions, and insula. Compared with the SCZ-nMetS group, the SCZ-MetS group showed significantly reduced GMV in the right superior orbitofrontal gyrus, as well as in the left amygdala, left insula, and temporal lobe (<i>p</i> < 0.05). Mediation analysis indicated that reduced GMV in the right superior orbitofrontal gyrus significantly mediated the association between MetS and deficits in executive function (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>MetS-related executive dysfunction may be partly associated with reduced GMV in the right superior orbitofrontal gyrus, suggesting a potential mediating role of this brain region.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"52539"},"PeriodicalIF":2.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-16eCollection Date: 2026-10-01DOI: 10.31083/AP53200
Şerife Gengeç Benli, Semra İçer, Turgay Batbat, Zeynep Ak
{"title":"Comparative Evaluation of Resting-State fMRI Representations for Schizophrenia Classification Using Deep Learning.","authors":"Şerife Gengeç Benli, Semra İçer, Turgay Batbat, Zeynep Ak","doi":"10.31083/AP53200","DOIUrl":"10.31083/AP53200","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia is a complex and heterogeneous psychiatric disorder characterized by widespread impairments in cognitive, emotional, and perceptual processes. The increasing demand for objective, biologically grounded biomarkers in clinical diagnostics has catalyzed significant interest in functional Magnetic Resonance Imaging (fMRI) integrated with deep learning-based methodologies. However, the prevailing literature relies on pre-derived features such as functional connectivity matrices, independent component analysis outputs, and time-series representations. These approaches often introduce additional computational costs, methodological complexity, and sensitivity to parameter selection, thereby limiting scalability.</p><p><strong>Methods: </strong>To address these limitations, this study proposes a simplified end-to-end deep learning framework that does not require derived features and instead learns directly from preprocessed fMRI (pre-fMRI) data. In addition, an Amplitude of Low-Frequency Fluctuation (ALFF)-based dimensionality reduction strategy was employed, enabling direct classification from resting-state fMRI data without requiring functional connectivity or correlation matrix computation. Resting-state fMRI data from publicly available datasets, including participants aged 18-62 years (individuals with schizophrenia: 78; healthy controls: 158), were modelled using multiple representations, including three-dimensional (3D) blood oxygen level-dependent (BOLD) volumes, ALFF maps, mean- and standard deviation-based statistical summaries, and four-dimensional (4D) spatiotemporal structures. These representations were evaluated using Convolutional Neural Network (CNN)-based approaches with five-fold cross-validation.</p><p><strong>Results: </strong>The findings clearly demonstrate that data representation, rather than model architecture, serves as the primary determinant of classification performance. The highest performance was achieved using ALFF-based 3D representations, with an accuracy of 80.10%. In contrast, 4D approaches that jointly model spatial and temporal information did not yield a significant performance improvement despite increased architectural complexity and computational cost. This suggests that biologically meaningful and information-rich signal representations play a more critical role than model depth or temporal modelling strategies.</p><p><strong>Conclusions: </strong>The proposed approach demonstrates that effective classification can be achieved without relying on complex derived features such as functional connectivity, offering a simpler, more computationally efficient, and generalizable framework. The findings challenge the prevailing trend toward increasing architectural complexity in the literature and emphasize the critical importance of data representation. This study provides valuable insights for developing more scalable, interpretable, and clinically applicable artificial int","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"53200"},"PeriodicalIF":2.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-16eCollection Date: 2026-10-01DOI: 10.31083/AP56362
Mao Tang, She-Hui Chang, Hang Qian, Chang-Yong Zhang, Bao-Liang Zhong
{"title":"Metabolic Syndrome Among Inpatients With Schizophrenia: Prevalence and Clinical Correlates.","authors":"Mao Tang, She-Hui Chang, Hang Qian, Chang-Yong Zhang, Bao-Liang Zhong","doi":"10.31083/AP56362","DOIUrl":"10.31083/AP56362","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a major physical comorbidity in schizophrenia and is associated with increased risks of cardiovascular disease, diabetes, and poor prognosis. This study investigated the prevalence of MetS and its clinical correlates among Chinese inpatients with schizophrenia, with particular attention to the metabolic-risk profiles of antipsychotic regimens.</p><p><strong>Methods: </strong>This multicenter cross-sectional study included 1024 inpatients with schizophrenia from two tertiary psychiatric hospitals in Central China. MetS was diagnosed according to the criteria of the Chinese Diabetes Society. Sociodemographic, clinical, medication, physical examination, and laboratory data were collected. Antipsychotic regimens were classified as non-high-risk, high-risk, or high-risk-plus-low-risk combinations. Multivariable logistic regression was used to identify factors independently associated with MetS.</p><p><strong>Results: </strong>Overall, 398 of 1024 patients met the criteria for MetS, yielding a prevalence of 38.9% (95% confidence interval (CI), 35.9%-41.9%). Compared with patients without MetS, those with MetS were more likely to be male, older, have a higher body mass index, have a longer illness duration, exhibit depressive symptoms, report a history of smoking and alcohol use, and have greater illness severity. In the multivariable analysis, male sex (adjusted odds ratio [aOR] = 1.65, 95% CI, 1.21-2.25), older age (aOR = 1.02, 95% CI, 1.00-1.03), illness duration >5 years (aOR = 1.55, 95% CI, 1.14-2.13), Calgary Depression Scale for Schizophrenia (CDSS)-defined depressive symptoms (aOR = 2.71, 95% CI, 1.87-3.92), and high-risk antipsychotic regimens (aOR = 1.54, 95% CI, 1.15-2.06) were independently associated with MetS. High-risk-plus-low-risk combination regimens and chlorpromazine-equivalent (CPZ-eq) dose were not significantly associated with MetS.</p><p><strong>Conclusions: </strong>MetS is highly prevalent in this sample of Chinese inpatients with schizophrenia. The findings highlight the associations of both patient-level characteristics and antipsychotic regimen composition with MetS, whereas the current CPZ-equivalent dose showed no significant association. Enhanced metabolic monitoring and individualized treatment strategies are warranted in inpatient schizophrenia care.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"56362"},"PeriodicalIF":2.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-16eCollection Date: 2026-10-01DOI: 10.31083/AP56107
Sergio Machado, Alberto Souza de Sá Filho, Rafael Ferreira-Garcia, Lucio Lage Gonçalves, Federica Sancassiani, Giulia Cossu, Alessandra Perra, Mauro Giovanni Carta, Henning Budde, José Carlos Appolinario, Antonio Egidio Nardi
{"title":"Beyond the Screen: Reframing Virtual Reality as an Accessibility Technology for Autistic Individuals Through the Social Model of Disability.","authors":"Sergio Machado, Alberto Souza de Sá Filho, Rafael Ferreira-Garcia, Lucio Lage Gonçalves, Federica Sancassiani, Giulia Cossu, Alessandra Perra, Mauro Giovanni Carta, Henning Budde, José Carlos Appolinario, Antonio Egidio Nardi","doi":"10.31083/AP56107","DOIUrl":"10.31083/AP56107","url":null,"abstract":"<p><p>Virtual Reality (VR) has been increasingly highlighted as a promising therapeutic tool for autistic individuals, with meta-analyses indicating significant benefits in social and emotional aspects. However, a substantial portion of this research has been conducted within a medical model of deficit correction, focused primarily on standardizing and normalizing autistic behavior. This article proposes a profound shift in this perspective, viewing VR as an environmental accessibility technology grounded in the Social Model of Disability. Supported by the principles of neurodiversity, we argue that the true utility of VR lies in reducing the barriers that generate disability, not in correcting neurological differences. A critical analysis of the safety literature examined here suggests that certain adverse effects appear to be overlooked or underreported in a substantial proportion of the studies reviewed. Symptoms such as cybersickness, sensory overload, anxiety, and post-session fatigue pose real and immediate risks when considering the sensory processing profiles of autistic individuals. Thus, to foster more ethical and sustainable practices, we propose four interconnected priorities: systematic safety research, participatory co-design led by the community itself, implementation science in real-world contexts, and outcome metrics that genuinely affirm neurodiversity. By redefining what constitutes success in an intervention, prioritizing environmental fit, autonomy, and quality of life over behavioral conformity, this shift aligns the development of immersive technologies with the lived experiences of the autistic community. In doing so, it transforms VR from a corrective mechanism into a tool for affirmation and ecological adaptation.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"56107"},"PeriodicalIF":2.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha psychiatryPub Date : 2026-10-14eCollection Date: 2026-10-01DOI: 10.31083/AP51021
Zhuo Jiang, Haining Song, Lingnan Gao, Chen Wei, Chenghao Zhang, Zhan Wang, Kun Li, Zhonggang Wang
{"title":"Physical Comorbidity, Clinical Correlates, and Inpatient Management Burden in Hospitalized Patients With Major Depressive Disorder.","authors":"Zhuo Jiang, Haining Song, Lingnan Gao, Chen Wei, Chenghao Zhang, Zhan Wang, Kun Li, Zhonggang Wang","doi":"10.31083/AP51021","DOIUrl":"10.31083/AP51021","url":null,"abstract":"<p><strong>Background: </strong>Major depressive disorder (MDD) is frequently accompanied by physical comorbidity, which may complicate inpatient assessment and management. However, large-scale patient-level studies investigating physical comorbidity and its impact on inpatient resource utilization among hospitalized patients with MDD remain limited. This study aimed to characterize the profile of physical comorbidity in MDD and examine its adjusted associations with indicators of inpatient management burden.</p><p><strong>Methods: </strong>In this large-scale cross-sectional study, we analyzed data from 8463 patients with MDD admitted to a major psychiatric center. Patients were stratified according to the presence or absence of physical comorbidity. We assessed the prevalence and spectrum of physical comorbidity, compared demographic and clinical characteristics between groups, and used multivariable regression models to identify factors associated with physical comorbidity, as well as to examine its associations with length of stay, internal medicine consultation, and the use of physical therapies.</p><p><strong>Results: </strong>Physical comorbidity was identified in 56.9% of hospitalized patients with MDD. Among those with physical comorbidity, 65.2% had physical multimorbidity (≥2 conditions). Diseases of the circulatory system (80.7%) and endocrine, nutritional, and metabolic diseases (35.4%) were the most common disease categories. Older age, farming occupation, and greater severity of depressive episodes were independently associated with physical comorbidity. Physical comorbidity was also associated with a longer length of stay and substantially higher odds of requiring internal medicine consultation.</p><p><strong>Conclusions: </strong>This large inpatient cohort demonstrates that physical comorbidity is common, multisystemic, and clinically relevant among hospitalized patients with MDD. These findings support the routine assessment of physical health and timely multidisciplinary care during hospitalization, particularly for older patients, farmers, and those with severe depressive episodes.</p>","PeriodicalId":72151,"journal":{"name":"Alpha psychiatry","volume":"27 5","pages":"51021"},"PeriodicalIF":2.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}